Compound heterozygosity for FSHD-sized alleles is compatible with life and may exhibit a phenotypic dosage effect, suggesting disease susceptibility involves intrinsic properties beyond residual D4Z4 repeat size.
Authors
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to viable FSHD compound heterozygosity; leaves open dosage effects on phenotype.
Wohlgemuth et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: